Tonix Pharmaceuticals announces AI collaboration with X-Chem

Tonix Pharmaceuticals announced that it has entered into an AI and ML research collaboration with X-Chem. Tonix’s TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense’s Defense Threat Reduction Agency for up to $34 million to advance the development of Tonix’s TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug submission and a first-in-human Phase 1 clinical study.